NEUROCRINE BIOSCIENCES INC (NBIX) Fundamental Analysis & Valuation

NASDAQ:NBIX • US64125C1099

Current stock price

131.045 USD
+0.82 (+0.63%)
Last:

This NBIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. NBIX Profitability Analysis

1.1 Basic Checks

  • NBIX had positive earnings in the past year.
  • In the past year NBIX had a positive cash flow from operations.
  • NBIX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years NBIX had a positive operating cash flow.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • NBIX has a Return On Assets of 10.33%. This is amongst the best in the industry. NBIX outperforms 93.60% of its industry peers.
  • Looking at the Return On Equity, with a value of 14.71%, NBIX belongs to the top of the industry, outperforming 93.80% of the companies in the same industry.
  • The Return On Invested Capital of NBIX (11.30%) is better than 93.99% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NBIX is significantly below the industry average of 27.75%.
Industry RankSector Rank
ROA 10.33%
ROE 14.71%
ROIC 11.3%
ROA(3y)9.06%
ROA(5y)7.61%
ROE(3y)13.03%
ROE(5y)10.93%
ROIC(3y)11.44%
ROIC(5y)10.33%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • NBIX has a Profit Margin of 16.73%. This is amongst the best in the industry. NBIX outperforms 92.64% of its industry peers.
  • NBIX's Profit Margin has declined in the last couple of years.
  • NBIX has a better Operating Margin (22.25%) than 94.19% of its industry peers.
  • In the last couple of years the Operating Margin of NBIX has declined.
  • Looking at the Gross Margin, with a value of 98.18%, NBIX belongs to the top of the industry, outperforming 97.48% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 22.25%
PM (TTM) 16.73%
GM 98.18%
OM growth 3Y9.73%
OM growth 5Y-6.6%
PM growth 3Y17.26%
PM growth 5Y-15.55%
GM growth 3Y-0.09%
GM growth 5Y-0.17%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NBIX Health Analysis

2.1 Basic Checks

  • NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, NBIX has more shares outstanding
  • NBIX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • NBIX has an Altman-Z score of 7.36. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.36, NBIX is in the better half of the industry, outperforming 76.16% of the companies in the same industry.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.36
ROIC/WACC1.19
WACC9.52%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.39 indicates that NBIX has no problem at all paying its short term obligations.
  • The Current ratio of NBIX (3.39) is comparable to the rest of the industry.
  • NBIX has a Quick Ratio of 3.30. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • NBIX has a Quick ratio of 3.30. This is comparable to the rest of the industry: NBIX outperforms 42.25% of its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.3
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. NBIX Growth Analysis

3.1 Past

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.64%, which is quite impressive.
  • NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.09% yearly.
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.45%.
  • Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 22.29% on average per year.
EPS 1Y (TTM)41.64%
EPS 3Y44.95%
EPS 5Y29.09%
EPS Q2Q%48%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y24.32%
Revenue growth 5Y22.29%
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.83% on average over the next years. This is a very strong growth
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.12% yearly.
EPS Next Y32.86%
EPS Next 2Y33.83%
EPS Next 3Y32.11%
EPS Next 5Y26.83%
Revenue Next Year22.91%
Revenue Next 2Y17.93%
Revenue Next 3Y15.2%
Revenue Next 5Y10.12%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

7

4. NBIX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 28.12, NBIX can be considered very expensive at the moment.
  • 92.05% of the companies in the same industry are more expensive than NBIX, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.66. NBIX is around the same levels.
  • Based on the Price/Forward Earnings ratio of 21.17, the valuation of NBIX can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, NBIX is valued cheaply inside the industry as 94.38% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 38.00. NBIX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 28.12
Fwd PE 21.17
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 93.41% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
  • 96.12% of the companies in the same industry are more expensive than NBIX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.57
EV/EBITDA 16.23
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NBIX's earnings are expected to grow with 32.11% in the coming years.
PEG (NY)0.86
PEG (5Y)0.97
EPS Next 2Y33.83%
EPS Next 3Y32.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBIX Dividend Analysis

5.1 Amount

  • NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NBIX Fundamentals: All Metrics, Ratios and Statistics

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/22/2026, 12:43:06 PM)

131.045

+0.82 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-05
Inst Owners100.45%
Inst Owner Change0%
Ins Owners1.11%
Ins Owner Change5.32%
Market Cap13.15B
Revenue(TTM)2.86B
Net Income(TTM)478.60M
Analysts84.44
Price Target185.06 (41.22%)
Short Float %4.62%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-22.89%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-18.85%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)2
Avg EPS beat(8)-28.82%
EPS beat(12)4
Avg EPS beat(12)-75.12%
EPS beat(16)4
Avg EPS beat(16)-70.76%
Revenue beat(2)1
Avg Revenue beat(2)2.05%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.81%
Min Revenue beat(4)-0.28%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.41%
Revenue beat(12)6
Avg Revenue beat(12)1.05%
Revenue beat(16)9
Avg Revenue beat(16)1.31%
PT rev (1m)3.04%
PT rev (3m)1.59%
EPS NQ rev (1m)-4.71%
EPS NQ rev (3m)-21.18%
EPS NY rev (1m)1.33%
EPS NY rev (3m)-14.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)1.54%
Revenue NY rev (3m)3.3%
Valuation
Industry RankSector Rank
PE 28.12
Fwd PE 21.17
P/S 4.6
P/FCF 17.57
P/OCF 16.8
P/B 4.04
P/tB 4.04
EV/EBITDA 16.23
EPS(TTM)4.66
EY3.56%
EPS(NY)6.19
Fwd EY4.72%
FCF(TTM)7.46
FCFY5.69%
OCF(TTM)7.8
OCFY5.95%
SpS28.5
BVpS32.41
TBVpS32.41
PEG (NY)0.86
PEG (5Y)0.97
Graham Number58.2979 (-55.51%)
Profitability
Industry RankSector Rank
ROA 10.33%
ROE 14.71%
ROCE 16.37%
ROIC 11.3%
ROICexc 18.25%
ROICexgc 18.25%
OM 22.25%
PM (TTM) 16.73%
GM 98.18%
FCFM 26.17%
ROA(3y)9.06%
ROA(5y)7.61%
ROE(3y)13.03%
ROE(5y)10.93%
ROIC(3y)11.44%
ROIC(5y)10.33%
ROICexc(3y)28.05%
ROICexc(5y)23.52%
ROICexgc(3y)28.9%
ROICexgc(5y)24.22%
ROCE(3y)16.58%
ROCE(5y)14.96%
ROICexgc growth 3Y-5.34%
ROICexgc growth 5Y-9.62%
ROICexc growth 3Y-3.9%
ROICexc growth 5Y-9.62%
OM growth 3Y9.73%
OM growth 5Y-6.6%
PM growth 3Y17.26%
PM growth 5Y-15.55%
GM growth 3Y-0.09%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 112.96%
Cap/Sales 1.19%
Interest Coverage 250
Cash Conversion 117.42%
Profit Quality 156.44%
Current Ratio 3.39
Quick Ratio 3.3
Altman-Z 7.36
F-Score6
WACC9.52%
ROIC/WACC1.19
Cap/Depr(3y)128.93%
Cap/Depr(5y)141.45%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.5%
Profit Quality(3y)154.84%
Profit Quality(5y)186.73%
High Growth Momentum
Growth
EPS 1Y (TTM)41.64%
EPS 3Y44.95%
EPS 5Y29.09%
EPS Q2Q%48%
EPS Next Y32.86%
EPS Next 2Y33.83%
EPS Next 3Y32.11%
EPS Next 5Y26.83%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y24.32%
Revenue growth 5Y22.29%
Sales Q2Q%28.33%
Revenue Next Year22.91%
Revenue Next 2Y17.93%
Revenue Next 3Y15.2%
Revenue Next 5Y10.12%
EBIT growth 1Y9.18%
EBIT growth 3Y36.42%
EBIT growth 5Y14.21%
EBIT Next Year10.97%
EBIT Next 3Y23.29%
EBIT Next 5Y18.73%
FCF growth 1Y34.37%
FCF growth 3Y32.36%
FCF growth 5Y28.04%
OCF growth 1Y31.46%
OCF growth 3Y32.12%
OCF growth 5Y27.92%

NEUROCRINE BIOSCIENCES INC / NBIX Fundamental Analysis FAQ

What is the fundamental rating for NBIX stock?

ChartMill assigns a fundamental rating of 7 / 10 to NBIX.


What is the valuation status for NBIX stock?

ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.


How profitable is NEUROCRINE BIOSCIENCES INC (NBIX) stock?

NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 7 / 10.


What is the financial health of NEUROCRINE BIOSCIENCES INC (NBIX) stock?

The financial health rating of NEUROCRINE BIOSCIENCES INC (NBIX) is 7 / 10.